Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

Key facts

Study ID
NCT07133308
Run by
Sun Pharmaceutical Industries, Inc.
People needed
355
Starts
2025-08-05
Expected to finish
2028-05-01
Last updated by the study team
2026-01-28

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.